Home Virology HCV

HCV

Latest

HCV

Gilead Grows Antiviral Pipeline with Novartis, DURECT Licensing Deals

Regulus Therapeutics has begun a restructuring that includes elimination of 60% of its workforce and a voluntary pause of its Phase I study for RGLS4326

HCV

Regulus Axing 60% of Workforce, Pauses Patient Recruitment for Lead Program

HCV

Ascletis Licenses Medivir HCV Drug Candidate for Greater China

HCV

Virus Hijacks MicroRNA to Ensure its Propagation